đŸ‘€ VP Ferrer

🔍 Search 📋 Browse đŸ·ïž Tags ❀ Favourites ➕ Add 🧬 Extraction
6
Articles
6
Name variants
Also published as: Evelina G Ferrer, Evelina G. Ferrer, I Ferrer, Juan C. Ferrer, Marc Ferrer,
articles
F Fadlallah, K Elshiwy, Y Elkeraie +1388 more · 2024 · World Journal of Clinical Oncology · added 2026-04-20
F Fadlallah, K Elshiwy, Y Elkeraie, Z Merjaneh, G Khoudari, MT Sarmini, M Gad, M Al-Husseini, A Saad, RL Siegel, KD Miller, NS Wagle, A Jemal, A Kumar, V Gautam, A Sandhu, K Rawat, A Sharma, L Saha, M Bretthauer, M LĂžberg, P Wieszczy, M Kalager, L Emilsson, K Garborg, M Rupinski, E Dekker, M Spaander, M Bugajski, Ø Holme, AG Zauber, ND Pilonis, A Mroz, EJ Kuipers, J Shi, MA HernĂĄn, HO Adami, J Regula, G Hoff, MF Kaminski, S Shinji, T Yamada, A Matsuda, H Sonoda, R Ohta, T Iwai, K Takeda, K Yonaga, Y Masuda, H Yoshida, M Zajkowska, B Mroczko, GJ Poston, J Figueras, F Giuliante, G Nuzzo, AF Sobrero, JF Gigot, B Nordlinger, R Adam, T Gruenberger, MA Choti, AJ Bilchik, Cutsem EJ Van, JM Chiang, MI D'Angelica, GJ Chang, AM Kaiser, S Mills, JF Rafferty, WD Buie, JR Monson, MR Weiser, J Rafferty, AE Blackmore, MT Wong, CL Tang, BL Green, HC Marshall, F Collinson, P Quirke, P Guillou, DG Jayne, JM Brown, J Mar, A Anton-Ladislao, O Ibarrondo, A Arrospide, S LĂĄzaro, N Gonzalez, M Bare, D Callejo, M Redondo, JM Quintana, S Kitano, M Inomata, J Mizusawa, H Katayama, M Watanabe, S Yamamoto, M Ito, S Saito, S Fujii, F Konishi, Y Saida, H Hasegawa, T Akagi, K Sugihara, T Yamaguchi, T Masaki, Y Fukunaga, K Murata, M Okajima, Y Moriya, Y Shimada, P Gavriilidis, K Katsanos, K Toritani, J Watanabe, K Nakagawa, Y Suwa, H Suwa, A Ishibe, M Ota, C Kunisaki, I Endo, T Matsuda, Y Sumi, K Yamashita, M Yamamoto, Y Matsuda, S Kanaji, T Oshikiri, T Nakamura, S Suzuki, Y Kakeji, RK Cleary, AM Morris, AL Halverson, KA Mirkin, AS Kulaylat, CS Hollenbeak, E Messaris, S Atallah, B Martin-Perez, M Albert, T deBeche-Adams, G Nassif, L Hunter, S Larach, MX BjĂžrn, SK Perdawood, Z Shen, Y Ye, Q Xie, K Jiang, S Wang, G Wang, Z Wang, Z Jiang, J Liu, J Zhao, J Li, A Arezzo, MA Bonino, F Ris, L Boni, E Cassinotti, DCC Foo, NF Shum, A Brolese, F Ciarleglio, DS Keller, R Rosati, Nardi P De, U Elmore, Romario U Fumagalli, MD Jafari, A Pigazzi, E Rybakov, M Alekseev, N Vettoretto, R Cirocchi, R Passera, E ForcignanĂČ, M Morino, SH Park, HM Park, KR Baek, HM Ahn, IY Lee, GM Son, FA Vuijk, DE Hilling, JSD Mieog, AL Vahrmeijer, A Hiroishi, T Morimoto, K Horikoshi, Y Nakajima, KL Baglan, RC Frazier, D Yan, RR Huang, AA Martinez, JM Robertson, JG Letschert, JV Lebesque, Boer RW de, AA Hart, H Bartelink, JY Wo, CJ Anker, JB Ashman, NA Bhadkamkar, L Bradfield, DT Chang, J Dorth, J Garcia-Aguilar, D Goff, D Jacqmin, P Kelly, NB Newman, J Olsen, AC Raldow, E Ruiz-Garcia, KB Stitzenberg, CR Jr Thomas, QJ Wu, P Das, V Paroder, TJ Fraum, S Nougaret, I Petkovska, GM Rauch, H Kaur, C Bascoul-Mollevi, S Gourgou, C Borg, PL Etienne, E Rio, E Rullier, B Juzyna, F Castan, T Conroy, RR Bahadoer, EA Dijkstra, Etten B van, CAM Marijnen, H Putter, EM Kranenbarg, AGH Roodvoets, ID Nagtegaal, RGH Beets-Tan, LK Blomqvist, T Fokstuen, Tije AJ Ten, J Capdevila, MP Hendriks, I Edhemovic, A Cervantes, PJ Nilsson, B Glimelius, de Velde CJH van, GAP Hospers, P Goffredo, FF Quezada-Diaz, JJ Smith, A Cercek, CSD Roxburgh, P Strombom, LKF Temple, GM Nash, JG Guillem, PB Paty, R Yaeger, ZK Stadler, K Seier, M Gonen, NH Segal, DL Reidy, A Varghese, J Shia, E Vakiani, AJ Wu, CH Crane, MJ Gollub, LB Saltz, V Vendrely, J Asselineau, P Rouanet, JJ Tuech, A Valverde, Chaisemartin C de, M Rivoire, B Trilling, M Jafari, G Portier, B Meunier, I Sieleznieff, M Bertrand, F Marchal, A Dubois, M Pocard, A Rullier, D Smith, N Frulio, E Frison, Q Denost, CC Fossum, JY Alabbad, LB Romak, CL Hallemeier, MG Haddock, M Huebner, EJ Dozois, DW Larson, J Simpson, JH Scholefield, L Feo, M Polcino, E Vinet, N Joharatnam-Hogan, W Wilson, KK Shiu, GK Fusai, B Davidson, D Hochhauser, J Bridgewater, K Khan, JY Luh, KV Albuquerque, C Cheng, RP Ermoian, N Nabavizadeh, H Parsai, JC Roeske, SE Weiss, RB Wynn, Y Yu, SA Rosenthal, A Hartford, S Gwynne, R Webster, R Adams, S Mukherjee, B Coles, J Staffurth, AC Hartford, JM Galvin, DC Beyer, TJ Eichler, GS Ibbott, B Kavanagh, CJ Schultz, ST Chao, LK Dad, LA Dawson, NB Desai, M Pacella, R Rengan, Y Xiao, KM Yenice, BS Teh, SY Woo, EB Butler, SS Lo, AJ Fakiris, EL Chang, NA Mayr, JZ Wang, L Papiez, RC McGarry, HR Cardenes, RD Timmerman, AB Sharabi, PT Tran, M Lim, CG Drake, TL Deweese, E Lavrova, MD Garrett, YF Wang, C Chin, C Elliston, M Savacool, M Price, LA Kachnic, DP Horowitz, KK Brock, CH Chiang, TY Chao, MY Huang, M Haque, MS Shakil, KM Mahmud, EJ Vaios, J Yan, C Wang, X Jiang, Y Wei, Q Wang, K Cui, X Xu, F Wang, L Zhang, T Mitin, AL Zietman, X Tian, K Liu, Y Hou, J Cheng, J Zhang, Y Hiroshima, H Ishikawa, M Murakami, M Nakamura, S Shimizu, T Enomoto, T Oda, M Mizumoto, K Nakai, T Okumura, H Sakurai, G Kraft, S Yamada, H Takiyama, Y Isozaki, M Shinoto, H Makishima, N Yamamoto, H Tsuji, DK Ebner, T Kamada, EG Chiorean, G Nandakumar, T Fadelu, S Temin, AE Alarcon-Rozas, S Bejarano, AE Croitoru, S Grover, PV Lohar, A Odhiambo, ER Garcia, C Teh, A Rose, B Zaki, MD Chamberlin, Dominguez O Hernandez, S Yilmaz, SR Steele, D Duarte, N Vale, XH You, YH Jiang, Z Fang, F Sun, Y Li, W Wang, ZJ Xia, XZ Wang, HQ Ying, L Xiong, Y Lou, L Wang, NN Baxter, EB Kennedy, E Bergsland, J Berlin, TJ George, S Gill, PJ Gold, A Hantel, L Jones, C Lieu, N Mahmoud, YN You, JA Meyerhardt, WJ Thompson, GA Piazza, H Li, L Liu, J Fetter, B Zhu, G Sperl, D Ahnen, R Pamukcu, BN Islam, DD Browning, M Cruz-Burgos, A Losada-Garcia, CD Cruz-HernĂĄndez, SA CortĂ©s-RamĂ­rez, I Camacho-Arroyo, V Gonzalez-Covarrubias, M Morales-Pacheco, SI Trujillo-Bornios, M RodrĂ­guez-Dorantes, P Dent, L Booth, JL Roberts, A Poklepovic, JF Hancock, N Arber, CJ Eagle, J Spicak, I RĂĄcz, P Dite, J Hajer, M Zavoral, MJ Lechuga, P Gerletti, J Tang, RB Rosenstein, K Macdonald, P Bhadra, R Fowler, J Wittes, SD Solomon, B Levin, J Peñarando, A Cañas, LM LĂłpez-SĂĄnchez, F Conde, S Guil-Luna, V HernĂĄndez, C Villar, C Morales-EstĂ©vez, la Haba-RodrĂ­guez J de, E Aranda, A RodrĂ­guez-Ariza, RK Phillips, MH Wallace, PM Lynch, E Hawk, GB Gordon, BP Saunders, N Wakabayashi, Y Shen, S Zimmerman, L Godio, M Rodrigues-Bigas, LK Su, J Sherman, G Kelloff, G Steinbach, CA Burke, R Phillips, JS Morris, R Slack, X Wang, S Patterson, FA Sinicrope, MA Rodriguez-Bigas, E Half, S Bulow, A Latchford, S Clark, WA Ross, B Malone, H Hasson, E Richmond, D Fina, L Franchi, R Caruso, I Peluso, GC Naccari, S Bellinvia, R Testi, F Pallone, G Monteleone, A Reinacher-Schick, A Schoeneck, U Graeven, I Schwarte-Waldhoff, W Schmiegel, C Stolfi, J SƂoka, M Madej, B Strzalka-Mrozik, AF Slater, JH Choi, JS Yoon, YW Won, BB Park, YY Lee, K Sasaki, NH Tsuno, E Sunami, K Kawai, K Hongo, M Hiyoshi, M Kaneko, K Murono, N Tada, T Nirei, K Takahashi, J Kitayama, M Selvakumaran, RK Amaravadi, IA Vasilevskaya, PJ O'Dwyer, LE Anselmino, MV Baglioni, G Reynoso, VR Rozados, OG Scharovsky, MJ Rico, M Menacho-MĂĄrquez, T AndrĂ©, C Boni, L Mounedji-Boudiaf, M Navarro, J Tabernero, T Hickish, C Topham, M Zaninelli, P Clingan, I Tabah-Fisch, Gramont A de, A Bonetti, F Rivera, JP Kuebler, HS Wieand, MJ O'Connell, RE Smith, LH Colangelo, G Yothers, NJ Petrelli, MP Findlay, TE Seay, JN Atkins, JL Zapas, JW Goodwin, L Fehrenbacher, RK Ramanathan, BA Conley, PJ Flynn, G Soori, LK Colman, EA Levine, KS Lanier, N Wolmark, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy, H Cortes-Funes, G Freyer, D Papamichael, Bail N Le, C Louvet, D Hendler, Braud F de, C Wilson, F Morvan, A Mohammed, NB Janakiram, M Brewer, K Vedala, VE Steele, CV Rao, AR BrĂĄs, P Fernandes, T Moreira, J Morales-Sanfrutos, E SabidĂł, AMM Antunes, A Valente, A Preto, C Teixeira-Guedes, RG Teixeira, Garcia M Helena, TS Morais, P Florindo, MF Piedade, V Moreno, C Ciudad, V Noe, YT Lee, YJ Tan, CE Oon, VV Padma, Z Koveitypour, F Panahi, M Vakilian, M Peymani, Forootan F Seyed, Esfahani MH Nasr, K Ghaedi, N Valeri, C Dearman, S Rao, D Watkins, N Starling, I Chau, D Cunningham, J Neumann, L Wehweck, S Maatz, J Engel, T Kirchner, A Jung, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, D Bets, M Mueser, A Harstrick, C Verslype, Cutsem E Van, G Fornasier, S Francescon, P Baldo, CH Köhne, E Hitre, J Zaluski, Chien CR Chang, A Makhson, G D'Haens, T PintĂ©r, R Lim, G Bodoky, JK Roh, G Folprecht, P Ruff, C Stroh, S Tejpar, M Schlichting, J Nippgen, P Rougier, I LĂĄng, MP Nowacki, S Cascinu, I Shchepotin, J Maurel, A Zubel, I Celik, F Ciardiello, TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, S Idziaszczyk, R Harris, D Fisher, SL Kenny, E Kay, JK Mitchell, A Madi, B Jasani, MD James, MJ Kennedy, B Claes, D Lambrechts, R Kaplan, JP Cheadle, CJ Allegra, RB Rumble, SR Hamilton, PB Mangu, N Roach, RL Schilsky, VK Morris, AB 3rd Benson, M Cho, KK Ciombor, C Cremolini, A Davis, DA Deming, MG Fakih, S Gholami, TS Hong, I Jaiyesimi, K Klute, H Sanoff, JH Strickler, S White, JA Willis, C Eng, F Petrelli, R Ardito, A Ghidini, A Zaniboni, M Ghidini, S Barni, G Tomasello, L Lo, D Patel, AR Townsend, TJ Price, JY Douillard, R Burkes, M Barugel, J Jassem, I KocĂĄkova, M BƂasiƄska-Morawiec, M Ć makal, JL Canon, M Rother, KS Oliner, M Wolf, J Gansert, TW Kim, A Elme, JO Park, AA Udrea, SY Kim, JB Ahn, RV Valencia, S Krishnan, N Manojlovic, X Guan, C Lofton-Day, AS Jung, E Vrdoljak, D Rossini, A Boccaccino, M Carullo, C Antoniotti, G Dima, P CiracĂŹ, F Marmorino, R Moretto, G Masi, T Liu, S Jiang, X Teng, L Zhong, M Liu, Y Jin, M Dong, Y Zhang, JY Zou, Y Wang, A Dasari, S Lonardi, R Garcia-Carbonero, E Elez, T Yoshino, A Sobrero, J Yao, P GarcĂ­a-Alfonso, J Kocsis, Gracian A Cubillo, A Sartore-Bianchi, T Satoh, V Randrian, J Tomasek, G Chong, AS Paulson, T Masuishi, J Jones, T CsƑszi, F Ghiringhelli, A Shergill, HS Hochster, J Krauss, A Bassam, M Ducreux, L Faugeras, S Kasper, D Arnold, S Nanda, Z Yang, WR Schelman, M Kania, D Dakowicz, R Bhattacharya, XC Ye, R Wang, X Ling, M McManus, F Fan, D Boulbes, LM Ellis, X Ye, L Xia, J Garcia, HI Hurwitz, AB Sandler, D Miles, RL Coleman, R Deurloo, OL Chinot, H Hurwitz, W Novotny, T Cartwright, J Hainsworth, W Heim, A Baron, S Griffing, E Holmgren, N Ferrara, G Fyfe, B Rogers, R Ross, F Kabbinavar, C Zhang, Y Lv, C Cao, J Lu, B Du, X Yang, Y Cui, Y Guo, R Lakomy, H Prenen, J PrausovĂĄ, T Macarulla, Hazel GA van, V Moiseyenko, D Ferry, J McKendrick, J Polikoff, A Tellier, R Castan, C Allegra, A Thakur, MR Chorawala, RS Patel, AL Cohn, R Obermannova, TE Ciuleanu, DC Portnoy, A Grothey, P Garcia-Alfonso, K Yamazaki, PR Clingan, L Simms, SC Chang, F Nasroulah, P Ge, N Wan, X Han, X Long, Y Bian, Z Gao, Y Bao, Y Fan, G Chen, P Fu, J Ros, M RodrĂ­guez-Castells, N Saoudi, I Baraibar, F Salva, E Élez, H Wasan, J Desai, F Loupakis, YS Hong, N Steeghs, TK Guren, HT Arkenau, A Gollerkeri, K Maharry, J Christy-Bittel, S Kopetz, DY Oh, YJ Bang, SJ Casak, MN Horiba, M Yuan, SJ Lemery, YL Shen, W Fu, JN Moore, Y Bi, D Auth, N Fesenko, PG Kluetz, R Pazdur, LA Fashoyin-Aje, T Vu, FX Claret, K Ng, C Wu, JM Hubbard, AL Coveler, C Fountzilas, A Kardosh, PM Kasi, HJ Lenz, DL Bajor, F Sanchez, M Stecher, W Feng, TS Bekaii-Saab, J Koury, M Lucero, C Cato, L Chang, J Geiger, D Henry, J Hernandez, F Hung, P Kaur, G Teskey, A Tran, Z Zhang, AS Shimu, HX Wei, Q Li, X Zheng, B Li, J Zheng, DM Pardoll, Y Shiravand, F Khodadadi, SMA Kashani, SR Hosseini-Fard, S Hosseini, H Sadeghirad, R Ladwa, K O'Byrne, A Kulasinghe, JA Seidel, A Otsuka, K Kabashima, HB Jie, Y Lei, N Gildener-Leapman, S Trivedi, T Green, LP Kane, RL Ferris, ME Keir, MJ Butte, GJ Freeman, AH Sharpe, M Wu, Q Huang, Y Xie, X Wu, H Ma, Y Xia, for Colorectal Cancer Immunotherapy, C for DE Research, LA Jr Diaz, BV Jensen, LH Jensen, C Punt, M Benavides, P Gibbs, la Fourchardiere C de, DT Le, WY Zhong, D Fogelman, P Marinello, T Andre, F Hirano, K Kaneko, H Tamura, H Dong, M Ichikawa, C Rietz, DB Flies, JS Lau, G Zhu, K Tamada, L Chen, MJ Overman, R McDermott, JL Leach, MA Morse, A Hill, M Axelson, RA Moss, MV Goldberg, ZA Cao, JM Ledeine, GA Maglinte, O Kooshkaki, A Derakhshani, N Hosseinkhani, M Torabi, S Safaei, O Brunetti, V Racanelli, N Silvestris, B Baradaran, V Singh, A Sheikh, MAS Abourehab, P Kesharwani, A GSK, M Lumish, J Sinopoli, J Weiss, M Lamendola-Essel, Dika IH El, N Segal, M Shcherba, R Sugarman, Z Stadler, B Rousseau, G Argiles, M Patel, A Desai, M Widmar, K Iyer, N Gianino, C Crane, PB Romesser, EP Pappou, P Paty, M Gollub, KA Schalper, T Watanabe, T Ishino, Y Ueda, J Nagasaki, T Sadahira, H Dansako, M Araki, Y Togashi, S Hashemzadeh, Z Asadzadeh, MA Shadbad, F Rasibonab, H Safarpour, V Jafarlou, AG Solimando, PK Singh, S Najafi, D Javadrashid, A Tarhini, KYM Wong, F Gelsomino, M Aglietta, MB Sawyer, A Hendlisz, B Neyns, S Abdullaev, A Memaj, M Lei, M Dixon, PM Boland, WW Ma, CH June, SR Riddell, TN Schumacher, A Mitra, A Barua, L Huang, S Ganguly, Q Feng, B He, H Du, J Yang, Q Zhang, J Shen, X Huang, M Wang, Y Huang, J Chen, Y Xu, W Zhao, Y Qi, Y Ou, C Qian, DJ Juat, SJ Hachey, J Billimek, Rosario MP Del, EL Nelson, CCW Hughes, JA Zell, E Martinis, C Ricci, C Trevisan, G Tomadini, S Tonon, Z Wu, M Yang, Y Cao, W Jia, T Zhang, H Huang, H Feng, Z Guo, Z Luo, X Ji, X Cheng, R Zhao, E Janssen, B Subtil, la Jara Ortiz F de, HMW Verheul, DVF Tauriello, Therapeutics Tizona, LLC Inc, Sankyo Co Daiichi, SE BioNTech, DS Neel, TG Bivona, A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, E Scala, A Cassingena, D Zecchin, M Apicella, G Migliardi, F Galimi, C Lauricella, C Zanon, T Perera, S Veronese, G Corti, A Amatu, M Gambacorta, M Sausen, VE Velculescu, P Comoglio, L Trusolino, Nicolantonio F Di, S Giordano, A Jahangiri, Lay M De, LM Miller, WS Carbonell, YL Hu, K Lu, MW Tom, J Paquette, TA Tokuyasu, S Tsao, R Marshall, A Perry, KM Bjorgan, MM Chaumeil, SM Ronen, G Bergers, MK Aghi, CJ LaFargue, P Amero, K Noh, LS Mangala, Y Wen, E Bayraktar, S Umamaheswaran, E Stur, SK Dasari, C Ivan, S Pradeep, W Yoo, C Lu, NB Jennings, V Vathipadiekal, W Hu, A Chelariu-Raicu, Z Ku, H Deng, W Xiong, HJ Choi, M Hu, T Kiyama, CA Mao, R Ali-Fehmi, MJ Birrer, N Zhang, G Lopez-Berestein, Franciscis V de, Z An, AK Sood, M Hao, S Hou, W Li, K Li, L Xue, Q Hu, L Zhu, Y Chen, H Sun, C Ju, YL Tang, DD Li, JY Duan, LM Sheng, J Manzi, CO Hoff, R Ferreira, A Pimentel, J Datta, AS Livingstone, R Vianna, P Abreu, GM Ramzy, M Norkin, T Koessler, L Voirol, M Tihy, D Hany, T McKee, N Buchs, M Docquier, C Toso, L Rubbia-Brandt, G Bakalli, S Guerrier, J Huelsken, P Nowak-Sliwinska, JD Fumet, A Hoos, AM Eggermont, S Janetzki, FS Hodi, R Ibrahim, A Anderson, R Humphrey, B Blumenstein, L Old, J Wolchok, F Tartari, M Santoni, L Burattini, P Mazzanti, A Onofri, R Berardi, J Zugazagoitia, C Guedes, S Ponce, I Ferrer, S Molina-Pinelo, L Paz-Ares, Velzen MJM van, S Derks, Grieken NCT van, Mohammad N Haj, Laarhoven HWM van, N Huyghe, P Baldin, den Eynde M Van, G Trimaglio, AF Tilkin-MariamĂ©, V Feliu, F LauzĂ©ral-Vizcaino, M Tosolini, C Valle, M Ayyoub, O Neyrolles, N Vergnolle, Y Rombouts, C Devaud, AD Kostic, E Chun, L Robertson, JN Glickman, CA Gallini, M Michaud, TE Clancy, DC Chung, P Lochhead, GL Hold, EM El-Omar, D Brenner, CS Fuchs, M Meyerson, WS Garrett, LS Pessoa, M Heringer, VP Ferrer, Maghvan P Vaseghi, S Jeibouei, ME Akbari, V Niazi, F Karami, A Rezvani, N Ansarinejad, M Abbasinia, G Sarvari, H Zali, R Talaie, A Dey, S Pathak, S Prasad, AS Zhang, H Zhang, XF Sun, A Banerjee Show less
Colorectal cancer (CRC) is the third most common cancer worldwide, and the second most common cause of cancer-related death. In 2020, the estimated number of deaths due to CRC was approximately 930000 Show more
Colorectal cancer (CRC) is the third most common cancer worldwide, and the second most common cause of cancer-related death. In 2020, the estimated number of deaths due to CRC was approximately 930000, accounting for 10% of all cancer deaths worldwide. Accordingly, there is a vast amount of ongoing research aiming to find new and improved treatment modalities for CRC that can potentially increase survival and decrease overall morbidity and mortality. Current management strategies for CRC include surgical procedures for resectable cases, and radiotherapy, chemotherapy, and immunotherapy, in addition to their combination, for non-resectable tumors. Despite these options, CRC remains incurable in 50% of cases. Nonetheless, significant improvements in research techniques have allowed for treatment approaches for CRC to be frequently updated, leading to the availability of new drugs and therapeutic strategies. This review summarizes the most recent therapeutic approaches for CRC, with special emphasis on new strategies that are currently being studied and have great potential to improve the prognosis and lifespan of patients with CRC. Show less
📄 PDF DOI: 10.5306/wjco.v15.i9.1136
review
Restrepo Guerrero, Andrés G., Andrés G. Restrepo Guerrero, Valeria R. Martinez +11 more · 2023 · Springer US · Springer · added 2026-04-20
This study is based on the premise that the application of chemical synthesis strategies to structurally modify commercial drugs by complexation with biometals is a valid procedure to improve their bi Show more
This study is based on the premise that the application of chemical synthesis strategies to structurally modify commercial drugs by complexation with biometals is a valid procedure to improve their biological effects. Our purpose is to synthesize a compound with greater efficacy than the original drug, able to enhance its antihypertensive and cardiac pharmacological activity. Herein, the structure of the coordination compound of Zn(II) and the antihypertensive drug olmesartan, [Zn(Olme)(H2O)2] (ZnOlme), is presented. After 8 weeks of treatment in SHR male rats, ZnOlme displayed a better blood pressure-lowering activity compared with olmesartan, with a noticeable effect even in the first weeks of treatment, while ZnCl2 showed similar results than the control. ZnOlme also reduced left ventricle (LV) weight and left ventricle/tibia length ratio (LV/TL), posterior wall thickness (PWT), and intraventricular septum in diastole (IVSd) suggesting its potential to prevent LV hypertrophy. Besides, ZnOlme reduced interstitial fibrosis (contents of collagen types I and III, responsible for giving rigidity and promoting vascular elasticity, respectively). The recovery of heart function was also evidenced by fractional shortening (diastolic left ventricular/systolic left ventricular) diameter determinations. Furthermore, ZnOlme increased the antioxidant capacity and prevented cardiac oxidative stress: it enhanced the reduction of reactive oxygen species generation, exerted a significant decrease in lipid peroxidation and enhanced glutathione contents in heart tissues compared to the control, Zn, and olmesartan treatments. Our results demonstrate that continuous oral administration of ZnOlme causes a better antihypertensive effect and grants enhancement of cardioprotection through antioxidant activity, in combination with hemodynamic improvement. Graphical Abstract Show less
no PDF DOI: 10.1007/s12011-023-03670-8
ROS Zn synthesis
Valeria R Martínez, María V Aguirre, Juan S Todaro +4 more · 2021 · Future medicinal chemistry · added 2026-04-20
Background: Angiotensin II receptor blockers were designed as therapeutic agents to block the binding site of the angiotensin II receptor type 1 (AT1R). Methodology: The structure of tel Show more
Background: Angiotensin II receptor blockers were designed as therapeutic agents to block the binding site of the angiotensin II receptor type 1 (AT1R). Methodology: The structure of telmisartan was modified by coordination to the biometal Zn(II), resulting in the compound ZnTelm. Its antihypertensive activity and cellular mechanisms in comparison to telmisartan were studied. Results: Compared with telmisartan, ZnTelm displayed stronger binding to AT1R (binding studies on AT1R-transfected human embryonic kidney cells) and a greater reduction of reactive oxygen species and cytosolic calcium concentration induced by angiotensin II. The antihypertensive activity of the complex (assessed in an N(G)-Nitro-L-arginine methyl ester-induced hypertension model) was significantly higher. ZnTelm also reduced hypertrophy in aortic artery rings and tubular collagen deposition. Conclusion: ZnTelm enhances the AT1R blockade and consequently its antihypertensive effect. Show less
no PDF DOI: 10.4155/fmc-2020-0093
Zn
Valeria R. Martínez, María V. Aguirre, Juan S. Todaro +2 more · 2021 · New Journal of Chemistry · Royal Society of Chemistry · added 2026-04-20
Cellular oxidative stress is considered an inducer of carcinogenesis but the association of reactive oxygen species (ROS) with cancer is sometimes contradictory. The antihypertensive drugs can Show more
Cellular oxidative stress is considered an inducer of carcinogenesis but the association of reactive oxygen species (ROS) with cancer is sometimes contradictory. The antihypertensive drugs candesartan and valsartan were reported to behave as antioxidant agents. In the present study, we prepared their Zn(II) coordination complexes, [ZnCand(H2O)2]·2H2O (ZnCand) and [ZnVals(H2O)2] (ZnVals), and determined that they also depleted ROS by the induction of a reductive state in response to glutathione (GSH) generation and decreased lung cancer cell viability (IC50 = 175 and 220 ”M, respectively), while being non-cytotoxic for normal lung fibroblasts (MRC5). The Zn complexes affected the mitochondria membrane, increased the pro- and anti-apoptotic protein ratio, Bax/Bcl-XL, and caspase-9 activation, by late apoptosis. Their co-incubation with N-acetylcysteine (NAC) exacerbated ROS reduction and increased cell death, whereas the H2O2 co-treatment restored the ROS values and normal cell growth. These data suggest that the excess reducing equivalents and low levels of ROS are also critical for the functioning of A549 cells. Show less
📄 PDF DOI: 10.1039/D0NJ02937H
A549 Co ROS Zn amino-acid anticancer coordination-chemistry mitochondria
María S. Islas, Islas, María S., Alicia Luengo +15 more · 2016 · Springer Berlin Heidelberg · Springer · added 2026-04-20
Abstract The coordination compound of the antihypertensive ligand irbesartan (irb) with copper(II) (CuIrb) was synthesized and characterized by FTIR, FT-Raman, UV–visible, reflectance and EPR spectros Show more
Abstract The coordination compound of the antihypertensive ligand irbesartan (irb) with copper(II) (CuIrb) was synthesized and characterized by FTIR, FT-Raman, UV–visible, reflectance and EPR spectroscopies. Experimental evidence allowed the implementation of structural and vibrational studies by theoretical calculations made in the light of the density functional theory (DFT). This compound was designed to induce structural modifications on the ligand. No antioxidant effects were displayed by both compounds, though CuIrb behaved as a weak 1,1-diphenyl-2-picrylhydrazyl radical (DPPH·) scavenger (IC50 = 425 ÎŒM). The measurements of the contractile capacity on human mesangial cell lines showed that CuIrb improved the antihypertensive effects of the parent medication. In vitro cell growth inhibition against prostate cancer cell lines (LNCaP and DU 145) was measured for CuIrb, irbesartan and copper(II). These cell lines have been selected since the angiotensin II type 1 (AT1) receptor (that was blocked by the angiotensin receptor blockers, ARB) has been identified in them. The complex exerted anticancer behavior (at 100 ÎŒM) improving the activity of the ligand. Flow cytometry determinations were used to determine late apoptotic mechanisms of cell death. Graphical Abstract Experimental and DFT characterization of an irbesartan copper(II) complex has been performed. The complex exhibits low scavenging activity against DPPH· and significant growth inhibition of LNCaP and DU 145 prostate cancer cell lines. Flow cytometry determinations were used to determine late apoptotic mechanisms of cell death. This compound improved the antihypertensive effect of irbesartan. This effect was observed earlier for the mononuclear Cu–candesartan complex, but not in structurally modified sartans forming dinuclear or octanuclear Cu–sartan compounds. Show less
📄 PDF DOI: 10.1007/s00775-016-1384-5
Cu DFT anticancer coordination-chemistry synthesis
Federico I. Rosell, Juan C. Ferrer, A. Grant Mauk · 1998 · Journal of the American Chemical Society · ACS Publications · added 2026-04-20
no PDF DOI: 10.1021/ja971756%2B
Fe amino-acid